With the deal, Agilent will acquire a 48% stake in Lasergen and will join the board. In addition, the new shareholder has the option to acquire the remaining shares of Lasergen until March 2, 2018, for an additional consideration of $105m.
The two companies will now collaborate on building a sequencing solutions workflow for clinical applications, based on Lasergen’s Lightning Terminators™ sequencing chemistry.
Founded in 2002 and led by Mimi Healy, Ph.D., President and CEO, Lasergen is research and development company dedicated to the advancement and commercialization of nucleotide chemistries with particular focus on sequencing.
While its proprietary photocleavable chemistry can be used in a wide variety of applications, the Lightning Terminators are specifically being developed as part of an Next-generation sequencing platform that includes chemistry, instrumentation and software.